Curis Inc (CRIS)

[Desert dweller]

de Sauvage presentation now available.

http://webcast.aacr.org/console/player/15176?mediaType=audio

From what I can tell it is well worth listening to although not a whole lot of new info. He did say that one of the 33 patients in the phase 1 study was probably mis diagnosed when admitted to the study and the tumor type he had, if they had diagnosed him properly at the beginning, they would have realized that he wouldn't have responded and would not have let him in the study. He was one of the 4 that were shown to have had disease progression out of the 33 enrolled. What that means to me is that the phase 1 study is even more impressive since instead of an 88% positive response rate it would have been over 92% when taking into account stable disease as well as partial and complete responses.

He discussed the Medulloblastoma patient who developed resistance and felt that the resistance could have been developed prior to the treatment and they isolated the resistance. He feels that possibly the resistance can be overcome with a cocktail approach and have identified a compound in which to test it. He said there could be other resistance types built up and they might be able to overcome them as well once the resistance type is determined.

Overall it was educational but nothing really new as far as I could tell but I don't understand the science behind it since I am a CPA and not a scientist and those with the correct background may have a different take. Onward and upward for Curis.